Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: A cohort study in the French national health insurance database

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 3, 2014, Pages 240-250

  Neumann, Anke ^a   Maura, Géric ^a   Weill, Alain ^a   Ricordeau, Philippe ^a   Alla, François ^b   Allemand, Hubert ^b  

^a Département des Etudes en Santé Publique Caisse Nationale de l'Assurance Maladie   (France)

^b Caisse Nationale d'Assurance Maladie des Travailleurs Salaries   (France)

Author keywords

Comparative effectiveness; Inverse probability of censoring weighting; Pharmacoepidemiology; Primary prevention; Rosuvastatin; Simvastatin; SNIIRAM (Syst me National d'Information Inter R gimes de l'Assurance Maladie)

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ROSUVASTATIN; SIMVASTATIN; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; FOLLOW UP; HEART DISEASE; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NATIONAL HEALTH INSURANCE; OUTCOME ASSESSMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; SEX DIFFERENCE; VASCULAR DISEASE; ANTAGONISTS AND INHIBITORS; BLOOD; COMPARATIVE STUDY; EPIDEMIOLOGY; FACTUAL DATABASE; FRANCE; PROCEDURES; PUBLIC HEALTH; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; CHOLESTEROL, LDL; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; FRANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PRIMARY PREVENTION; PYRIMIDINES; RETROSPECTIVE STUDIES; ROSUVASTATIN CALCIUM; SIMVASTATIN; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84895472602     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3544     Document Type: Article

References (64)

1. World Health Organization, World Heart Federation, World Stroke Organization. Global atlas on cardiovascular disease prevention and control: policies, strategies, and interventions. Published 2011. http://www.who.int/cardiovascular_diseases/publications/atlas_cvd/en/ (Accessed 21 January 2013).
2. Laslett LJ, Alagona P Jr, Clark BA 3rd, et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol 2012; 60: S1-S49. DOI: 10.1016/j.jacc.2012.11.002
3. Vaartjes I, Reitsma JB, de Bruin A, et al. Nationwide incidence of first stroke and TIA in the Netherlands. Eur J Neurol 2008; 15: 1315-1323. DOI: 10.1111/j.1468-1331.2008.02309.x
4. Tuppin P, Neumann A, Simon D, et al. Characteristics and management of diabetic patients hospitalized for myocardial infarction in France. Diabetes Metab 2010; 36: 129-136. DOI: 10.1016/j.diabet.2009.10.003
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 19: 1383-1389.
6. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996; 335: 1001-1009.
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-1357.
8. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001; 357: 1063-1068.
9. Klungel OH, Heckbert SR, de BA, et al. Lipid-lowering drug use and cardiovascular events after myocardial infarction. Ann Pharmacother 2002; 36: 751-757.
10. Zhou Z, Rahme E, Abrahamowicz M, et al. Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. CMAJ 2005; 172: 1187-1194.
11. Wei L, Ebrahim S, Bartlett C, Davey PD, Sullivan FM, MacDonald TM. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. Br Med J 2005; 330: 821.
12. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007; 11: 1-160, iii-iv.
13. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
14. Sever PS, Dahlöf B, Poulter NR, et al. ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
15. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
16. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. Br Med J 2009; 338: b2376. DOI: 10.1136/bmj.b2376
17. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
18. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207. DOI: 10.1056/NEJMoa0807646
19. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011; 19: CD004816. DOI: 10.1002/14651858.CD004816.pub5
20. Minder CM, Blaha MJ, Horne A, Michos ED, Kaul S, Blumenthal RS. Evidence-based use of statins for primary prevention of cardiovascular disease. Am J Med 2012; 125: 440-446. DOI: 10.1016/j.amjmed.2011.11.013
21. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681. DOI: 10.1016/S0140-6736(10)61350-5
22. Mihaylova B, Emberson J, Blackwell L, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-590. DOI: 10.1016/S0140-6736(12)60367-5
23. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582-587.
24. * Trial). Am J Cardiol 2003; 92: 152-160.
25. Clearfield MB, Amerena J, Bassand JP, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia-prospective study to evaluate the use of low doses of the statins atorvastatin and rosuvastatin (PULSAR). Trials 2006; 7: 35.
26. Goettsch WG, Yin DD, Alemao E, Klungel OH, Stalenhoef AF, Herings RM. Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study. Curr Med Res Opin 2004; 20: 1025-1033.
27. Bullano MF, Wertz DA, Yang GW, et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy 2006; 26: 469-478.
28. Kamat SA, Gandhi SK, Davidson M. Comparative effectiveness of rosuvastatin versus other statin therapies in patients at increased risk of failure to achieve low-density lipoprotein goals. Curr Med Res Opin 2007; 23: 1121-1130.
29. Heintjes EM, Hirsch MW, van der Linden MW, O'Donnell JC, Stalenhoef AF, Herings RM. LDL-C reductions and goal attainment among naive statin users in the Netherlands: real life results. Curr Med Res Opin 2008; 24: 2241-2250. DOI: 10.1185/03007990802264487
30. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 2003; 326: 1423.
31. Edwards JE, Moore RA. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam Pract 2003; 4: 18.
32. Fox KM, Gandhi SK, Ohsfeldt RL, Blasetto JW, Bays HE. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States. Curr Med Res Opin 2007; 23: 2125-2133.
33. Heintjes EM, Penning-van Beest FJ, Johansson S, Stalenhoef AF, Herings RM. Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study. Curr Med Res Opin 2009; 25: 2621-2629. DOI: 10.1185/03007990903269112
34. Motsko SP, Russmann S, Ming EE, Singh VP, Vendiola RM, Jones JK. Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular events-a cohort study in 395 039 patients from clinical practice. Pharmacoepidemiol Drug Saf 2009; 18: 1214-1222. DOI: 10.1002/pds.1843
35. Grimaldi-Bensouda L, Rossignol M, Danchin N, et al. The Effect of Statins on the Risk of First Non-Fatal Myocardial Infarction: A Population-Based Observational Study Using the PGRx Information System. American Heart Association scientific sessions 2012. 7 November 2012.
36. Dieleman JP, van Wyk JT, van Wijk MA, et al. Differences between statins on clinical endpoints: a population-based cohort study. Curr Med Res Opin 2005; 21: 1461-1468.
37. Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States. Clin Ther 2008; 30: 195-205. DOI: 10.1016/j.clinthera.2008.01.003
38. Willke RJ, Zhou S, Vogel RA. Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience. Curr Med Res Opin 2008; 24: 2873-2882. DOI: 10.1185/03007990802405577
39. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
40. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307-1316.
41. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-1080.
42. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatine vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437-2445.
43. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
44. Fintel D, Joyce A, Mackell J, Graff J, Kuntze E, Ollendorf DA. Reduced mortality rates after intensive statin therapy in managed-care patients. Value Health 2007; 10: 161-169.
45. Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique 2010; 58: 286-290
46. ATIH, Website of Technical Hospitalization Information Agency (ATIH). Available from www.atih.sante.fr, accessed 26 February 2013 [Website in French].
47. Rey G, Jougla E, Fouillet A, Hémon D. Ecological association between a deprivation index and mortality in France over the period 1997-2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health 2009; 9: 33.
48. Therneau T, Grambsch P. Modeling Survival Data: Extending the Cox Model. Springer-Verlag: New York, 2000.
49. Robins JM, Finkelstein D. Correcting for non-compliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 2000; 56: 779-788.
50. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11: 561-570.
51. Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease (with discussion). Epidemiology 2008; 19: 766-779.
52. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning: Prediction, Inference and Data Mining (2nd edn), Springer-Verlag: New York, 2009.
53. Howe CJ, Cole SR, Chmiel JS, Muñoz A. Limitation of inverse probability-of-censoring weights in estimating survival in the presence of strong selection bias. Am J Epidemiol 2011; 173: 569-577. DOI: 10.1093/aje/kwq385
54. Haute Autorité de santé. Efficacité et efficience des hypolipémiants: une analyse centrée sur les statines. Evaluation des technologies de santé - Analyse médico-économique. July 2010. http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-07/synthese_efficacite_et_efficience_des_hypolipemiants_-_une_analyse_centree_sur_les_statines.pdf (accessed 28 January 2013)
55. de Lorgeril M, Salen P, Abramson J, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med 2010; 170: 1032-1036. DOI: 10.1001/archinternmed.2010.184
56. Sakshaug S, Furu K, Karlstadt Ø, Rønning M, Skurtveit S. Switching statins in Norway after new reimbursement policy-a nationwide prescription study. Br J Clin Pharmacol 2007; 64: 476-481.
57. Halava H, Helin-Salmivaara A, Junnila J, Huupponen R. Selective prescribing of simvastatin and atorvastatin by patient characteristics at treatment initiation over a 7-year period in Finland. Eur J Clin Pharmacol 2009; 65: 927-933. DOI: 10.1007/s00228-009-0664-1
58. Ohlsson H, Chaix B, Merlo J. Therapeutic traditions, patient socioeconomic characteristics and physicians' early new drug prescribing - a multilevel analysis on rosuvastatin prescription in south Sweden. Eur J Clin Pharmacol 2009; 65: 141-150. DOI: 10.1007/s00228-008-0569-4
59. Delaney JA, Oddson BE, McClelland RL, Psaty BM. Estimating ethnic differences in self-reported new use of antidepressant medications: results from the Multi-Ethnic Study of Atherosclerosis. Pharmacoepidemiol Drug Saf 2009; 18: 545-553. DOI: 10.1002/pds.1751
60. Desai RJ, Ashton CM, Deswal A, et al. Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiol Drug Saf 2012; 21: 233-240. DOI: 10.1002/pds.2175. Epub 2011 Jul 22
61. Liao JK. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 2002; 86: 5-18.
62. van Wissen S, Trip MD, Smilde TJ, de Graaf J, Stalenhoef AF, Kastelein JJ. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 2002; 165: 361-366.
63. Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003; 108: 426-431.
64. Ruidavets JB, Bataille V, Dallongeville J, et al. Alcohol intake and diet in France, the prominent role of lifestyle. Eur Heart J 2004; 25: 1153-1162.